Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analys...

Full description

Saved in:
Bibliographic Details
Main Authors: P. A. Shesternya, A. I. Zagrebneva, O. V. Antipova, Yu. V. Arbuzova, I. G. Bannikova, L. V. Belozertseva, E. A. Bogdanova, S. A. Bykova, E. A. Vasilenko, I. B. Vinogradova, S. Yu. Davidyan, O. E. Epifanova, E. V. Zemerova, M. V. Zlobin, L. V. Ivanova, N. A. Ilyina, L. V. Ilyushina, E. P. Klyuchnikova, A. V. Makevnina, E. R. Myasoutova, E. E. Nakonechnaya, A. B. Pavlova, T. V. Plaksina, A. V. Rybin, T. S. Salnikova, L. V. Solodovnikova, A. V. Fedorova, I. A. Cherencova, E. V. Jakovleva, S. P. Yakupova, E. N. Alekseev, A. M. Lila
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2025-04-01
Series:Современная ревматология
Subjects:
rheumatoid arthritis
olokizumab
il-6 inhibitor
real world evidence
Online Access:https://mrj.ima-press.net/mrj/article/view/1738
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://mrj.ima-press.net/mrj/article/view/1738

Similar Items